Corticosteroid avoidance in pediatric renal transplantation: Can it be achieved?

Pediatric Drugs

Volumn 6, Issue 5, 2004, Pages 273-288

  Vidhun, Jayakumar R ^a   Sarwal, Minnie M ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; DEFLAZACORT; HYDROCORTISONE; MEPREDNISONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

AVASCULAR NECROSIS; CARDIOVASCULAR DISEASE; CATARACT; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DIABETES MELLITUS; DRUG SAFETY; DRUG WITHDRAWAL; FRACTURE; GRAFT SURVIVAL; GROWTH RETARDATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCREASED APPETITE; INFECTION; INSOMNIA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MOOD DISORDER; MUSCLE ATROPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; WOUND HEALING IMPAIRMENT;

EID: 7044241293     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200406050-00002     Document Type: Review

References (79)

1. Hricik DE, Almawi WY, Strom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation 1994; 57 (7): 979-89
2. Seikaly M, Ho PL, Emmett L, et al. The 12th annual report of the North American Pediatric Renal Transplant Cooperative Study: renal transplantation from 1987 through 1998. Pediatr Transplant 2001; 5 (3): 215-31
3. North American Pediatric Renal Transplant Cooperative Society (NAPRTCS). NAPRTCS annual report; 2002 [online]. Available from URL: http:// www.spitfire.emmes.com/study/ped/ [Accessed 2003 Jun 4)
4. Schroeder TJ, First RM, Gaber OA. Monitoring and management of immunosuppression in pediatric transplant patients. Clin Immunotherapy 1995; 4 (6): 425-44
5. Ettenger R. The practical problems of prednisone in pediatric renal transplantation. Transplant Proc 2001; 33 (1-2): 989-91
6. Evans ER. Immune response in pediatric renal transplantation. New York (NY): Wiley-Liss Inc., 1994
7. Ettenger RB. Age and the immune response in pediatric renal transplantation. Eur J Pediatr 1992; 151 Suppl. 1: S7-8
8. Schroeder TJ, Ryckman FC, Hurtubise PE. Immunological monitoring during and after OKT3 therapy in children. Clinic Transpl 1991; 5: 191-6
9. Salvatierra Jr O. Pediatric renal transplantation. Transplant Proc 2000; 32 (3): 634-5
10. United Network of Organ Sharing (UNOS). The UNOS 2002 annual report [online]. Available from URL: http:/www.unos.org [Accessed 2003 Jun 4]
11. Sarwal MM, Cecka JM, Millan MT, et al. Adult-size kidneys without acute tubular necrosis provide exceedingly superior long-term graft outcomes for infants and small children: a single center and UNOS analysis. United Network for Organ Sharing. Transplantation 2000; 70 (12): 1728-36
12. Gjertson DW, Cecka JM. Determinants of long-term survival of pediatric kidney grafts reported to the United Network for Organ Sharing kidney transplant registry. Pediatr Transplant 2001; 5 (1): 5-15
13. Rossi SJ, Schroeder TJ, Hariharan S, et al. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Saf 1993; 9 (2): 104-31
14. Fryer JP, Benedetti E, Gillingham K, et al. Steroid-related complications in pediatric kidney transplant recipients in the cyclosporine era. Transplant Proc 1994; 26(1): 91-2
15. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33 (5): 829-39
16. Kannel WB. Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors (the Framingham experience). Am J Cardiol 1996; 77 (6): 6B-11B
17. Fryer JP, Granger DK, Leventhal JR, et al. Steroid-related complications in the cyclosporine era. Clin Transplant 1994 Jun; 8 (3 Pt 1): 224-9
18. Bishop GA, Sun J, DeCruz DJ, et al. Tolerance to rat liver allografts: III. Donor cell migration and tolerance-associated cytokine production in peripheral lymphoid tissue. J Immunol 1996; 156: 4925-31
19. Wang C, Sun J, Sheil AG, et al. A short course of methylprednisolone immunosuppression inhibits both rejection and spontaneous acceptance of rat liver allografts. Transplantation 2001; 72 (1): 44-51
20. Smiley ST, Csizmadia V, Gao W, et al. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction. Transplantation 2000; 70 (3): 415-9
21. Opelz G. Influence of treatment with cyclosporine, azathioprine and steroids on chronic allograft failure: the Collaborative Transplant Study. Kidney Int Suppl 1995; 52: S89-92
22. Conti F, Dousset B, Archambeau D, et al. Enhanced risk of steroid-resistant acute rejection following pretransplant steroid therapy in liver graft recipients. Transplantation 1995; 60 (10): 1104-8
23. Sharland A, Yan Y, Wang C, et al. Evidence that apoptosis of activated T cells occurs in spontaneous tolerance of liver allografts and is blocked by manipulations which break tolerance. Transplantation 1999; 68 (11): 1736-45
24. Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5 (11): 1303-7
25. Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5(11): 1298-302
26. Satterwhite T, Chua MS, Hsieh SC, et al. Increased expression of cytotoxic effector molecules: different interpretations for steroid-based and steroid-free immunosuppression. Pediatr Transplant 2003; 7 (1): 53-8
27. Tejani A, Fine R, Alexander S, et al. Factors predictive of sustained growth in children after renal transplantation: the North American Pediatric Renal Transplant Cooperative Study. J Pediatr 1993; 122 (3): 397-402
28. Hokken-Koelega AC, Stijnen T, de Jong RC, et al. A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplant. Kidney Int Suppl 1996; 53: S128-34
29. Maxwell H, Rees L. Randomised controlled trial of recombinant human growth hormone in prepubertal and pubertal renal transplant recipients: British Association for Pediatric Nephrology. Arch Dis Child 1998; 79 (6): 481-7
30. Guest G, Berard E, Crosnier H, et al. Effects of growth hormone in short children after renal transplantation: French Society of Pediatric Nephrology. Pediatr Nephrol 1998; 12 (6): 437-46
31. Fine RN, Stablein D, Cohen AH, et al. Recombinant human growth hormone post-renal transplantation in children: a randomized controlled study of the NAPRTCS. Kidney Int 2002; 62 (2): 688-96
32. Ratcliffe CJ, Dudley CR, Higgins RM, et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348 (9028): 643-8
33. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9 (11): 2129-34
34. McGeown MG, Douglas JF, Brown WA, et al. Advantages of low dose steroid from the first day after renal transplantation. Transplantation 1980; 29 (4): 287-9
35. Buckels JA, Barnes AD. Low-dose steroid regimens after renal transplantation [letter]. Lancet 1982; I (8283): 1250
36. Feldhoff C, Goldman AI, Najarian JS, et al. A comparison of alternate day and daily steroid therapy in children following renal transplantation. Int J Pediatr Nephrol 1984; 5 (1): 11-4
37. Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J Pediatr 1992; 120 (5): 721-5
38. Jabs K, Sullivan EK, Avner ED, et al. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function: a report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1996; 61 (1): 31-6
39. Ferraris JR, Pasqualini T, Legal S, et al. Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation: the Deflazacort Study Group. Pediatr Nephrol 2000; 14 (7): 682-8
40. Ferraris JR, Pennisi P, Pasqualini T, et al. Effects of deflazacort immunosuppression on long-term growth and growth factors after renal transplantation. Pediatr Nephrol 1997; 11 (3): 322-4
41. Hricik DE, Schulak JA. Metabolic effects of steroid withdrawal in adult renal transplant recipients. Kidney Int Suppl 1993; 43: S26-9
42. Chao SM, Jones CL, Powell HR, et al. Triple immunosuppression with subsequent prednisolone withdrawal: 6 years' experience in paediatric renal allograft recipients. Pediatr Nephrol 1994; 8 (1): 62-9
43. Ingulli E, Sharma V, Singh A, et al. Steroid withdrawal, rejection and the mixed lymphocyte reaction in children after renal transplantation. Kidney Int Suppl 1993; 43: S36-9
44. Ingulli E, Tejani A, Markell M. The beneficial effects of steroid withdrawal on blood pressure and lipid profile in children post-transplantation in the cyclosporine era. Transplantation 1993; 55 (5): 1029-33
45. Roberti I, Reisman L, Lieberman KV, et al. Risk of steroid withdrawal in pediatric renal allograft recipients (a 5-year follow-up). Clin Transplant 1994; 8 (4): 405-8
46. Reisman L, Lieberman KV, Burrows L, et al. Follow-up of cyclosporine-treated pediatric renal allograft recipients after cessation of prednisone. Transplantation 1990; 49 (1): 76-80
47. Motoyama O, Hasegawa A, Ohara T, et al. A prospective trial of steroid cessation after renal transplantation in pediatric patients treated with cyclosporine and mizoribine. Pediatr Transplant 1997; 1 (1): 29-36
48. Ellis D. Growth and renal function after steroid-free tacrolimus-based immunosuppression in children with renal transplants. Pediatr Nephrol 2000; 14 (7): 689-94
49. Shapiro R, Jordan ML, Scantlebury VP, et al. Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc 1998; 30 (4): 1375-7
50. Maiorca R, Cristinelli L, Brunori G, et al. Prospective controlled trial of steroid withdrawal after six months in renal transplant patients treated with cyclosporine. Transplant Proc 1988; 20 (3 Suppl. 3): 121-5
51. Mahalati K, Kahan BD. A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus: cyclosporine a combination therapy. Transplant Proc 2001; 33 (7-8): 3232-3
52. Chakrabarti P, Wong HY, Scantlebury VP, et al. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 2000; 70 (5): 760-4
53. Grewal HP, Thistlethwaite Jr JR, Loss GE, et al. Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. Transplant Proc 1998; 30 (4): 1378-9
54. Nowacka-Cieciura E, Durlik M, Cieciura T, et al. Steroid withdrawal after renal transplantation: risks and benefits. Transplant Proc 2002; 34 (2): 560-3
55. Schulak JA, Mayes JT, Moritz CE, et al. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients. Transplantation 1990; 49 (2): 327-32
56. Stratta RJ, Armbrust MJ, Oh CS, et al. Withdrawal of steroid immunosuppression in renal transplant recipients. Transplantation 1988; 45 (2): 323-8
57. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts: the Canadian Multicentre Transplant Study Group. CMAJ 1992; 147 (5): 645-57
58. Vincenti F, Monaco A, Grinyo J, et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3 (3): 306-11
59. Matas AJ, Ramcharan T, Paraskevas S, et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant 2001; 1 (3): 278-83
60. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55 (5): 993-5
61. Ponticelli C, Tarantino A, Montagnino G. Steroid withdrawal in renal transplant recipients. Transplant Proc 2001; 33 (1-2): 987-8
62. Hricik DE, Whalen CC, Lautman J, et al. Withdrawal of steroids after renal transplantation: clinical predictors of outcome. Transplantation 1992; 53 (1): 41-5
63. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66 (12): 1736-40
64. Sarwal MM, Vidhun JR, Alexander SR, et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003 Nov; 76 (9): 1331-9
65. Adams RW, Chapman RL, Smallwood GA. Steroid withdrawal in liver transplant recipients. Prog Transplant 2001; 11 (3): 217-23
66. Diem HV, Sokal EM, Janssen M, et al. Steroid withdrawal after pediatric liver transplantation: a long-term follow-up study in 109 recipients. Transplantation 2003; 75 (10): 1664-70
67. Greig P, Lilly L, Scudamore C, et al. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl 2003; 9 (6): 587-95
68. Belli LS, de Carlis L, Rondinara G, et al. Early cyclosporine monotherapy in liver transplantation: a 5-year follow-up of a prospective, randomized trial. Hepatology 1998; 27 (6): 1524-9
69. Eason JD, Loss GE, Blazek J, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001; 7 (8): 693-7
70. Birkeland SA. Steroid-free immunosuppression in renal transplantation. Lancet 1996; 348 (9034): 1105-6
71. Birkeland SA. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation 2001; 71 (8): 1089-90
72. Birkeland SA, Larsen KE, Rohr N. Pediatric renal transplantation without steroids. Pediatr Nephrol 1998; 12 (2): 87-92
73. Cole E, Landsberg D, Russell D, et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72 (5): 845-50
74. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 1999; 96 (13): 7462-6
75. Stock PG, Lantz M, Light S, et al. In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients. Transplant Proc 1996; 28 (2): 915-6
76. Schwartz GJ, Haycock GB, Edelmann Jr CM, et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58 (2): 259-63
77. Sarwal M, Vidhun J, Ho M, et al. Single center and NAPRTCS analysis confirm unprecedented growth patterns in steroid-free immunosuppression [abstract]. Am J Transplant 2003; 3 (s5): 166
78. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62 (3): 1060-7
79. Sarwal MM, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001; 72 (1): 13-21